Silencing of CDC42 inhibits contraction and growth-related functions in prostate stromal cells, which is mimicked by ML141

CDC42 Regulates the ERK Pathway to Improve Oxygen‒Glucose Deprivation/Reoxygenation-Induced Neural Oxidative Stress and Apoptosis

CDC42 regulates neural morphology, differentiation, and injury and modifies oxidative stress and neural immune infiltration, but its effect on oxygen-glucose deprivation/reoxygenation (OGD/R)-induced neural injury has not been reported. Therefore, this study aimed to investigate the effects of CDC42 overexpression on neural injury and oxidative stress during the OGD/R process. The OGD/R cellular model was established by culturing HT22 cells in glucose-free medium under hypoxic conditions for 2, 4, or 6 h and then transferring them to complete medium and a standard environment for another 24 h. CDC42 and negative control overexpression vectors (oeCDC42 and oeNC) were transfected into HT22 cells; afterwards, PD98059, a specific ERK inhibitor, was added along with or without oeCDC42. CDC42 expression, cell viability, and superoxide dismutase (SOD) activity were reduced, but cell apoptosis and reactive oxygen species (ROS) were elevated after OGD/R induction in a time-dependent manner. oeCDC42 decreased cell apoptosis and ROS and increased SOD activity in OGD/R-induced HT22 cells, but it did not significantly increase cell viability. Moreover, oeCDC42 positively regulated p-ERK and p-c-Fos expression. In addition, PD98059 decreased cell viability and SOD activity but increased cell apoptosis and ROS in OGD/R-induced HT22 cells; moreover, the effects of PD98059 combined with oeCDC42 also showed similar trends compared to oeCDC42 alone regarding the above indexes. CDC42 can ameliorate OGD/R-induced neural oxidative stress and apoptosis by regulating the ERK pathway.

The role of RhoA-ROCK signaling in benign prostatic hyperplasia: a review

Benign prostatic hyperplasia (BPH) is a common urological disease in middle-aged and elderly men. The main pathological mechanisms of BPH include static factors that increase prostate volume and dynamic factors that increase prostate tension. The RhoA/ROCK signaling pathway is a classical pathway that regulates cell contraction, migration, and growth. In this review, we summarize the potential role of RhoA/ROCK signaling in the development of BPH. The RhoA/ROCK signaling pathway can enhance the contraction of prostate smooth muscle through the Ca2+ sensitization pathway and increase passive tension in the prostate through tissue fibrosis. Additionally, RhoA/ROCK signaling promotes cell proliferation by regulating cell division and may influence apoptosis by affecting the actin cytoskeleton. Furthermore, risk factors, such as inflammation, metabolic syndrome, and hormonal changes, can upregulate RhoA/ROCK signaling, which in turn promotes these risk factors, eventually leading to the development of BPH. Given the role of RhoA/ROCK signaling in regulating multiple pathogenic factors of BPH, this pathway represents a promising molecular target for BPH treatment and warrants further study.

Isoform-independent promotion of contractility and proliferation, and suppression of survival by with no lysine/K kinases in prostate stromal cells

With no lysine/K kinases (WNKs) promote vasocontraction and vascular smooth muscle cell proliferation. In the prostate, smooth muscle contraction and growth may be critical for the development and medical treatment of voiding symptoms in benign prostatic hyperplasia. Here, we examined the effects of isoform-specific WNK silencing and of the WNK inhibitor WNK463 on growth-related functions and contraction in prostate stromal cells, and in human prostate tissues. Impacts of WNK silencing by transfection of cultured stromal cells with isoform-specific siRNAs were qualitatively and quantitatively similar for each WNK isoform. Effects of silencing were largest on cell death (3-5 fold increase in annexin V-positive/7-AAD-positive cells), on proliferation rate, Ki-67 mRNA expression and actin organization (reduced around two-thirds). Contraction in matrix contraction assays and viability were reduced to a lower degree (approximately half), but again to a similar extent for each WNK isoform. Effects of silencing were quantitatively and qualitatively reproduced by 10 μM WNK463, while 1 μM still induced cell death and breakdown in actin organization, without affecting proliferation or viability. Using 500 nM and 10 μM, WNK463 partly inhibited neurogenic and U46619-induced contractions of human prostate tissues (around half), while inhibition of α1-adrenergic contractions (around half) was limited to 10 μM. All four WNK isoforms suppress cell death and promote proliferation in prostate stromal cells. WNK-driven contraction of stromal cells appears possible, even though to a limited extent. Outcomes of isoform-specific WNK silencing can be fully reproduced by WNK463, including inhibition of smooth muscle contraction in human prostate tissues, but require high concentrations.